Developing pancreatic secretory trypsin inhibitor of molecular target therapy for pancreatic cancer with pancreatic secretory trypsin inhibitor antibodies.

用聚乙二醇液与免疫小鼠的脾细胞和Sp2/OAG-14细胞骨髓瘤融合，并在更换介质后两周内确认有无抗体产生，这是一种反复的抗体产生，但由于它停滞于杂交瘤的产生，所以将8倍的PSTI免疫雌性Balb/C小鼠，用PSTI现有的单抗进行致敏实验。Spink作为Spink的一种新功能，正在进行的研究中可能通过自噬调控参与促进胰腺癌的生长，但在单剂量交织瞬时作为人PSTI的单抗-Tofaji它才被认为是过度活跃的。

The fusion with PEG solution in the spleen cells of immunized mice and Sp2/OAg-14 cell mouse myeloma, and to confirm the presence or absence of antibody production in two weeks after the medium was replaced, it was trial and error the production of antibodies, but because it was bogged down in hybridoma create , was administered to 8 times intraperitoneally 8 weeks antigen (PSTI) to female Balb / C mice were subjected to experiments with PSTI existing monoclonal antibodies that were sensitized. Is allowed to induce pancreatitis in the administration of a single, severity was only varies with the dose.As a new function of SPINK, proceeded under study may be involved in growth promotion of pancreatic cancer via autophagy control, but woven transient in a single dose as human PSTI monoclonal antibodies - the Tofaji it was only acknowledge hyperactivity.